$HALO 8-K SEC Filings

(d) On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders ...

INDENTURE, dated as of September 22, 2026, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee,...

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

SAN DIEGO, CA, September 16, 2026 — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amo...